Benzodiazepine prescribing for schizophrenia occurs in clinical practice and antipsychotic trials. This review examined the clinical outcomes for benzodiazepines in schizophrenia.
Method
A systematic search identified randomised controlled trials that evaluated benzodiazepines in comparison with placebo or antipsychotics, and also as adjuncts to antipsychotics. Relevant clinical outcome data was extracted.
Results
Twenty six studies were included with some reporting multiple comparisons. Seven short-term studies compared benzodiazepines with placebo: benzodiazepine superiority was found in two out of five studies for global improvements and two out of four studies for psychiatric/behavioural outcomes. Eleven studies compared benzodiazepines with first-generation antipsychotics (FGAs): four out of nine studies (including two long-term studies) reported greater global improvements for antipsychotics; four out of five studies showed no treatment differences for psychiatric/behavioural outcomes. Fourteen studies compared benzodiazepines (as adjunct to antipsychotics) vs antipsychotics alone (mostly FGAs); benzodiazepine superiority was found for global improvement in one out of eight studies and inferiority in two out of eight short-term studies whereas superiority was found for psychiatric/behavioural outcomes in three out of 12 short-term studies and inferiority in three out of 12 studies.
Conclusion
Benzodiazepine superiority over placebo was found for global, psychiatric and behavioural outcomes, but inferiority to antipsychotics on longer-term global outcomes. Conflicting evidence exists regarding the addition of benzodiazepines to antipsychotics; thus the use of benzodiazepines in clinical practice and antipsychotic trials should be limited.
BattagliaJ (2005) Pharmacological management of acute agitation. Drugs65: 1207–1222.
7.
BeggCChoMEastwoodS. (1996) Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA276: 637–639.
8.
BitterLChouJC-YUngvariGS. (2003) Prescribing for inpatients with schizophrenia: An international multi-center comparative study. Pharmacopsychiatry36: 143–149.
9.
BodenWE (1992) Meta-analysis in clinical trials reporting: Has a tool become a weapon?Am J Cardiol69: 681–686.
10.
Dell’ossoBLaderM (2013) Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry28: 7–20.
11.
*CarpenterWTBuchananRWKirkPatrickB. (1999) Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry156: 299–303.
12.
CarpenterWTKoenigJI (2008) The evolution of drug development in schizophrenia: Past issues and future opportunities. Neuropsychopharmacology33: 2061–2079.
13.
ChakosMHGlickIDMillerAL. (2006) Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv57: 1094–1101.
14.
*CheungHK (1981) Schizophrenics fully remitted on neuroleptics for 3–5 years—to stop or continue drugs?Br J Psychiatry138: 490–494.
15.
ChouinardGRoss-ChouinardAAnnableL. (1980) Extrapyramidal rating scale. Can J Neurol Sci7: 233.
16.
*ChouinardGAnnableLTurnierL. (1993) A double-blind randomized clinical trial of rapid tranquilization with IM clonazepam and IM haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiat38: S114–121.
17.
*CsernanskyJGRineySJLombrozoL. (1988) Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms. Arch Gen Psychiat45: 655–659.
18.
DeeksJJHigginsJPTAltmanDG (2011) Assessing risk of bias in included studies. In: HigginsJPTGreenS (eds) Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley & Sons.
19.
DoldMLeuchtMD (2012) Efficacy and acceptability of benzodiazepine augmentation of antipsychotics in schizophrenia and schizophrenia-like psychoses: A meta-analysis of randomized controlled trials. Schizophr Res136: S264. [Conference Abstract]
20.
DoldMTardyMKhorsandV. (2012) Benzodiazepines for schizophrenia. Cochrane DB Syst Rev11.
21.
*DorevitchAKatzNZemishianyZ. (1999) Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry156: 142–144.
22.
EggerMSmithGDSterneJAC (2001) Uses and abuses of meta-analysis. Clin Med1: 478–484.
23.
EndicottJSpitzerRLFleissJL. (1976) The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiat33: 766–771.
24.
*FangMChenHLiLH. (2012) Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. Int Clin Psychopharm27: 107–113.
25.
FeighnerJPRobinsEGuzeSB. (1972) Diagnostic criteria for use in psychiatric research. Arch Gen Psychiat26: 57–63.
26.
Food and Drug Administration (FDA) (2013) Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Updated May17, 2013. Last (accessed 6 March 2014).
27.
FountoulakisKNSamaraMTSiamouliM (2013) Burning issues in the meta-analysis of pharmaceutical trials for depression. J Psychopharmacol28: 106–117.
28.
GilliesDBeckAMcCloudA. (2010). Benzodiazepines for psychosis-induced aggression or agitation. Cochrane DB Syst Rev.
29.
GilliesDSampsonSBeckA. (2013) Benzodiazepines for psychosis-induced aggression or agitation. Cochrane DB Syst Rev.
30.
*GundlachREngelhardtDMHankoffL. (1966) A double-blind outpatient study of diazepam valium and placebo. Psychopharmacologia9: 81–92.
31.
GuyW (1976) ECDEU assessment manual for psychopharmacology. Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs.
32.
*GuzIMoraesRSartorettoJN (1972) The therapeutic effects of lorazepam in psychotic patients treated with haloperidol: A double-blind study. Curr Ther Res, 14: 767–774.
33.
*HankoffL DRudorferLPaleyHM. (1962) A reference study of ataraxics. A two-week double blind outpatient evaluation. J New Drugs2: 173–178.
34.
*HanlonTEOtaKYAgallianosDD. (1969) Combined drug treatment of newly hospitalized, acutely ill psychiatric patients. Dis Nerv Syst30: 104–116.
35.
*HanlonTEOtaKYKurlandAA (1970) Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine. Dis Nerv Syst31: 171–176.
36.
HawCStubbsJ (2007) Benzodiazepines‚ a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital. J Psychopharmacol21: 645–649.
37.
*HoldenJMItilTMKeskinerA. (1968) Thioridazine and chlordiazepoxide,alone and combined, in the treatment of chronic schizophrenia. Compr Psychiatry9: 633–643.
38.
HonigfeldGGillisRDKlettCJ (1965) Nurses’ observation scale for inpatient evaluation: A new scale for measuring improvement in chronic schizophrenia. J Clin Psychol21: 65–71.
39.
JayaramMRattenhalltRDAdamsCE (2012) Where does evidence from new trials for schizophrenia fit with the existing evidence: A case of the emperor’s new clothes?Schizophr Res Treatment Article ID 625738. doi:10.1155/2012/625738
40.
Joint Formulary Committee (2011) British National Formulary (BNF) 62. London: Pharmaceutical Press.
41.
KaragianisJNovickDPecenakJ. (2009) Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO): Baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract63: 1578–1588.
42.
KaySRFiszbeinAOplerLA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull13: 261–276.
43.
KempASSchoolerNRKalaliAH. (2010) What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?Schizophr Bull36: 504–509.
44.
LangleGSteinertTWeiserP. (2012) Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr Scand125: 372–381.
45.
LernerYLwowELevitinA. (1979) Acute high-dose parenteral haloperidol treatment of psychosis. Am J Psychiatry136: 1061–1064.
46.
*LingjaerdeOEngstrandEEllingsenP. (1979) Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients: A double-blind clinical trial. Curr Ther Res26: 505–514.
47.
*LingjaerdeO (1982) Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. Acta Psychiatr Scand65: 339–354.
LundCEMortimerAMRogersD. (1991) Motor, volitional and behavioural disorders in schizophrenia. 1: Assessment using the Modified Rogers scale. Br J Psychiatry158: 323–327.
50.
*MaculansGA (1964) Comparison of diazepam, chlorprothixene and chlorpromazine in chronic schizophrenic patients. Dis Nerv Syst25: 164–168.
51.
MannC (1990) Meta-analysis in the breech. Science249: 476–480.
52.
McGorryPAlvarez-JimenezMKillackeyE (2013) Antipsychotic medication during the critical period following remission from first-episode psychosis: Less is more. JAMA Psychiatry70: 898–900.
53.
*MerlisSTurnerWJKrumholzW (1962) A double blind comparison of diazepam, chlordiazepoxide, and chlorpromazine in psychotic patients. J Neuropsychiatry3: 133–138.
54.
*MichauxMHKurlandAAAgallianosDD (1966) Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients. Curr Ther Res8: 117–152.
55.
MoherDHopewellSSchulzKF. (2010) CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. BMJ340: 869.
*MorphyMA (1986) A double-blind comparison of alprazolam and placebo in the treatment of anxious schizophrenic outpatients. Curr Ther Res40: 551–560.
58.
*NestorosJNSuranyi-CadotteBESpeesRC. (1982) Diazepam in high doses is effective in schizophrenia. Progress Neuro-Psychopharmacol Biol Psychiatry6: 513–516.
59.
*NishikawaTTsudaATanakaM. (1982) Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology77: 301–304.
60.
NovickDBousonoMSuarezD. (2005) Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Progress Neurosychopharmacol Biol Psychiatry29: 972–982.
61.
OverallJEGorhamDR (1962) The brief psychiatric rating scale. Psychol Rep10:790–812.
62.
ParkesCM (1963) Interhospital and intrahospital variations in the diagnosis and severity of schizophrenia. Br J Prev Soc Med17: 85–89.
63.
ProcyshynRMHonerWGWuTK. (2010) Persistent antipsychotic polypharmacy and excessive dosing in the com-munity psychiatric treatment setting: A review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry71: 566–573.
64.
RabinowitzJWerbeloffNKinonB. (2012) Effects of benzodiazepine and other hypnotic use on efficacy results in placebo controlled antipsychotic trials: Lessons learned from the NewMeds repository of RCT data from AstraZeneca, Eli Lilly, Lundbeck and Pfizer. Schizophr Res136: S1–S375.
65.
ShinfukuMUchidaHTsutsumiC. (2012) How psychotropic polypharmacy in schizophrenia begins: A longitudinal perspective. Pharmacopsychiatry45: 133–137.
66.
SimpsonGMAngusJWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr ScandS212: 11–19
67.
SuokasJTSuvisaariJMHaukkaJ. (2013) Description of long-term polypharmacy among schizophrenia outpatients. Soc Psychiatry Psychiatr Epidemiol48: 631–638.
68.
*StevensAStevensIMahalA. (1992) Haloperidol and lorazepam combined: Clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. Pharmacopsychiatry256: 273–277.
69.
TaylorDPatonCKapurS (2012) The Maudsley Prescribing Guidelines 11th Edition. Chichester: Wiley-Blackwell.
70.
TiihonenJSuokasJTSuvisaariJM. (2012) Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiat69: 476–483.
71.
*UngvariGSChiuHFKChowLY. (1999) Lorazepam for chronic catatonia: A randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology142: 393–398.
72.
VaresMSaetrePStrålinP. (2011) Concomitant medication of psychoses in a lifetime perspective. Human Psychopharmacol26: 322–331.
73.
VolzAKhorsandVGilliesD. (2007) Benzodiazepines for schizophrenia. Cochrane DB Syst Rev1.
74.
WolkowitzOMPickarD (1991) Benzodiazepines in the treatment of schizophrenia. A review and re-appraisal. Am J Psychiatry148: 714–726.
75.
WunderinkLNieboerRMWiersmaD. (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry70: 913–920.
76.
*WyantMBDiamondIO’NealE. (1990) The use of midazolam in acutely agitated psychiatric patients. Psychopharmacol Bull261: 126–129.
77.
YudofskySCSilverJMJacksonW. (1986) The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry143: 35–39.
78.
ZimbroffDL (2008) Pharmacological control of acute agitation. CNS Drugs2: 199–212.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
